Efficacy and safety of the ustekinumab biosimilar ABP 654 in patients with moderate-to-severe plaque psoriasis: a randomized double-blinded active-controlled comparative clinical study over 52 weeks.
Saved in:
| Title: | Efficacy and safety of the ustekinumab biosimilar ABP 654 in patients with moderate-to-severe plaque psoriasis: a randomized double-blinded active-controlled comparative clinical study over 52 weeks. |
|---|---|
| Authors: | Blauvelt A; Oregon Medical Research Center, Portland, OR, USA., Papp K; Alliance Clinical Trials Probity Medical Research, Waterloo, ON, Canada.; Department of Medicine, Division of Dermatology, University of Toronto, Toronto, ON, Canada., Trivedi M; Amgen Inc., Thousand Oaks, CA, USA., Barragan C; Amgen Inc., Thousand Oaks, CA, USA., Chow V; Amgen Inc., Thousand Oaks, CA, USA., Mytych DT; Amgen Inc., Thousand Oaks, CA, USA., Yamauchi P; Dermatology Institute and Skin Care Center, Inc. Clinical Science Institute, Santa Monica, CA, USA., Crowley J; Bakersfield Dermatology and Skin Cancer Medical Group, Bakersfield, CA, USA., Franklin J; Amgen Inc., Thousand Oaks, CA, USA. |
| Source: | The British journal of dermatology [Br J Dermatol] 2025 Apr 28; Vol. 192 (5), pp. 826-836. |
| Publication Type: | Journal Article; Randomized Controlled Trial; Comparative Study; Multicenter Study |
| Journal Info: | Publisher: Oxford University Press Country of Publication: England NLM ID: 0004041 Publication Model: Print Cited Medium: Internet ISSN: 1365-2133 (Electronic) Linking ISSN: 00070963 NLM ISO Abbreviation: Br J Dermatol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
